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Background: Everolimus (RAD001) is an orally administered mTOR inhibitor that is well known for its antitumor
efficacy and that has been approved for the treatment of several solid tumors, including renal cell carcinoma. In
gastric cancer (GC), despite previous preclinical and phase I/II studies suggesting the promising efficacy of
everolimus in previously treated AGC, more recent trials revealed that only certain subsets of patients might benefit
from treatment with everolimus.
Case presentation: A 26-year-old man with metastatic gastric cancer with multiple liver lesions was treated with
everolimus after failure of 1st-line and 2nd-line chemotherapy. A durable partial response was achieved for over
2 years. After progression from initial everolimus treatment, sequential cytotoxic chemotherapies were tried but
failed rapidly. Everolimus was re-tried as salvage chemotherapy (re-treatment), and the patient achieved stable
disease for 1 year until his death. Subsequent mutational analysis and immunohistochemical (IHC) staining with the
tumor tissues just before re-treatment with everolimus revealed a PIK3CA hotspot mutation and pS6 overexpression
in the primary tumor. After two cycles of everolimus re-treatment, the overexpression of pS6 became nearly absent
in follow-up IHC staining.
Conclusions: Everolimus monotherapy was satisfactory in a patient with refractory metastatic GC harboring PIK3CA
and pS6 aberrations. These molecular alterations might be potential biomarkers that can predict the treatment
response of everolimus, particularly in the terms of durable disease control. This case suggests and emphasizes that
close evaluation of biomarkers in tumor tissue may be essential for identifying highly favorable groups among
various subpopulations with AGC.Background
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(PKB or Akt) and mammalian target of rapamycin (mTOR)
signaling pathway plays an essential role in cell growth, pro-
tein translation, autophagy, and metabolism, which is
mainly activated by various growth factor receptors (i.e.,
HER2 (human epidermal growth factor receptor-2)) or by
phosphatase and tensin homolog (PTEN) mutation. Activa-
tion of the PI3K/Akt/mTOR signaling pathway is well* Correspondence: ykkang@amc.seoul.kr
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unless otherwise stated.established to be related to tumorigenesis and cancer pro-
gression in many types of tumors, which could further con-
tribute to acquired resistance to various anti-neoplastic
agents. In human gastric cancer (GC), PI3K/Akt and
mTOR are known to be activated in approximately 30%
and 60% of patients, respectively [1,2]. Therefore, in the era
of molecular-targeted agents, inhibition of the mTOR path-
way represents a novel therapeutic strategy in the treatment
of GC.
mTOR is a key down-stream protein kinase of the PI3K/
Akt signaling pathway, and everolimus (RAD001) is a novel
macrolide derivative of rapamycin that inhibits mTOR,
thereby preventing phosphorylation of its downstreamis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the treatment of renal cell carcinoma and other several can-
cer types, the clinical benefit and safety profiles of everoli-
mus in previously treated GC have been explored in several
preclinical and phase I/II studies [3-6]. In a more recent
phase III trial, however, everolimus monotherapy failed to
significantly improve overall survival (OS) in patients with
refractory AGC [7]. These intriguing findings suggest that
treatment with everolimus may be beneficial only in a subset
of GC patients who have been previously treated. In this
context, the identification of biomarkers for everolimus
seems to be clinically crucial for the selection of patients
most likely to benefit from the treatment and ultimately to
optimize the efficacy of everolimus.
Herein, we present a case of successful treatment with
everolimus in a patient with previously heavily treated
AGC, who was found to harbor concurrent dysregula-
tion in PIK3CA and pS6.
Case presentation
A 26-year-old Korean male was diagnosed with stage IV
poorly differentiated gastric adenocarcinoma of the lower
body with multiple liver metastases in August 2009. The
initial diagnosis was made at an outside hospital using
abdominopelvic computed-tomography (CT) and endo-
scopic biopsy of stomach. The pathologic specimen at the
time of diagnosis was not procured. The patient wasFigure 1 The patient received initial treatment of everolimus 10 mg/d
2 months during the initial treatment period. CT scans reveal the diffuse liv
2 months of everolimus 10 mg/d, partial response was achieved (B).initially treated with systemic chemotherapies, including
three cycles of S-1 and subsequently four cycles of FOL-
FOX chemotherapy, resulting in the progression of liver
metastasis. After second-line chemotherapy, the patient
was transferred to our institute (Asan medical center,
Seoul, Korea) for further management in September 2008.
Baseline tumor tissue was obtained via endoscopic forceps
biopsy before treatment. As third-line chemotherapy, the
patient was enrolled in an open-labeled, phase II trial
evaluating the efficacy of everolimus 10 mg/day, and he
achieved a partial response by the Response Evaluation
Criteria in Solid Tumors (RECIST) as the best response
after 1 year and 2 months (Figure 1A and B). The tumor
remained stable with a partial response over 2 years in this
initial treatment of everolimus. However, after 29 months
of initial everolimus treatment, abdominopelvic CT re-
vealed the progression of liver metastasis. An episodic
pneumonia due to streptococcus occurred right after dis-
ease evaluation, and the patient underwent antibiotic
treatment for a month. Subsequently, the patient under-
went salvage chemotherapy with FOLFIRI but failed after
3 cycles with disease progression. Sequential three cycles
of oral paclitaxel and six cycles of docetaxel chemotherapy
were applied to the patient for 4 months to maintain
stable disease. During the period of docetaxel treatment,
however, the patient suffered from general weakness ac-
companied by poor compliance and eventually failed theas the third-line chemotherapy. CT scans were taken every
er metastases before treatment with everolimus (A). After 1 year and
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the everolimus monotherapy as salvage chemotherapy.
Before re-treatment with everolimus, according to re-
sults from our previous retrospective data [8], we investi-
gated the mutation of the PIK3CA gene in the tumor
tissue obtained just before re-treatment of everolimus.
DNA was amplified using oligonucleotide primers specific
for mutational hotspots in exons 9 and 20 of human
PIK3CA. The mutational analysis revealed one of the clas-
sical activating PIK3CA hotspot mutations: E545K in exon
9 (Figure 2). In addition, we performed immunohisto-
chemical (IHC) staining for pS6 at serine 235/236
(pS6Ser235/236, 1:150 dilution, rabbit monoclonal, Cell Sig-
naling Techmology) and at serine 240/244 (pS6Ser240/244,
1:200 dilution, rabbit polyclonal, Cell Signaling Technol-
ogy) and PTEN (1:50 dilution, rabbit monoclonal, Cell
Signaling Technology) with tumor tissues obtained just
before and 2 months after re-treatment with everolimus.
The tumor cells were strongly positive for pS6 in more
than 50% of the tumor, and PTEN was weakly positive in
tumor cells relative to the internal controls of endothelial
cells (Figure 3A). From January 2012 to February 2013,
during the re-treatment with 10 mg everolimus daily, we
evaluated the tumor every 2 months by APCT and ob-
served stationary state of liver metastasis. After two months
of everolimus re-treatment, the patient underwent follow-
up endoscopic biopsy and IHC staining for pS6 and PTEN.
Strikingly, the tumor cells in the follow-up biopsy were
completely negative for pS6, whereas the intensity of PTEN
was notably increased in all tumor cells (Figure 3B). As a
result of re-treatment with everolimus, this patient was able
to maintain stable disease for more than 1 year but unfortu-
nately died in March 2013 (Figure 4).
Conclusions
mTOR acts by directly phosphorylating two primary
downstream targets of mTORC1, activating ribosomalFigure 2 Mutation analysis of the PIK3CA gene was performed on ga
re-treatment, revealing one of the classical activating PIK3CA mutatioprotein S6 kinase 1 (S6K1) and inhibiting translational
repressor 4E-binding protein 1 (4EBP1). S6K1 phosphor-
ylates the S6 protein of the 40s ribosomal subunit at sev-
eral sites, including Ser 235/236 and Ser 240/244,
leading to the initiation of protein synthesis [9]. Everoli-
mus inhibits the ability of mTOR to phosphorylate S6K1
and 4EBP1, thereby inducing G0/G1 arrest and inhib-
ition of cell-cycle propagation in cancer cells [8-10]. Al-
though it is well known that tumors with mutations in
the mTOR pathways are uniquely susceptible to mTOR
inhibitor therapy, the anti-proliferative efficacy of evero-
limus depends on the type of cell lines, which exhibit
different sensitivities to everolimus [9-11].
Although the first phase II trial on patients with AGC
revealed the robust efficacy of disease control rate (DCR)
for everolimus [5], the results of the latest phase III
GRANITE-1 study were somewhat disappointing. How-
ever, this study at the time suggested that everolimus
might exhibit activity in a subset of heavily pretreated
AGC patients, which urged the development of predictive
biomarkers to select the subset of patients with favorable
sensitivity for the drug [7]. Therefore, great efforts in last
decade focused on exploring the biomarkers for everoli-
mus [8,10,12,13], which identified various potential bio-
markers in vitro and in vivo. In several previous studies,
PIK3CA/PTEN genomic aberrations were suggested as
strong predictors of everolimus sensitivity. The docu-
mented mutations of PIK3CA were mostly missense mu-
tations and clustered in two lesions consisting of three
hotspots (E542K, E545K, and H1047) [2,10,13-15]. In sev-
eral preclinical data, loss of staining on IHC was observed
in aberrations of PTEN, and the level of expression mark-
edly increased after treatment with everolimus in GC cell
lines [14-17]. It is generally accepted assumption with sev-
eral preclinical data that clinically effective everolimus
administration should provide a degree and duration of
S6K1 inhibition in peripheral blood and tumor tissues. Instroscopic biopsy specimen obtained before everolimus
ns at hotspot E545K in exon 9.
Figure 3 Immunohistochemical (IHC) staining for pS6 (serine 235/236 and serine 240/244) and PTEN was performed just before and
during the everolimus re-treatment. All photographs were taken at 200 X magnification. Before everolimus re-treatment, the tumor cells
exhibited strong positivity for pS6 in more than 50% of the tumor, whereas PTEN was weakly positive in tumor cells compared with the internal
controls of endothelial cells (A). After 2 months of everolimus re-treatment, the tumor cells in the follow-up biopsy were completely negative for
pS6. However, the intensity of PTEN was notably increased in all tumor cells (B).
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related to increased sensitivity toward everolimus [10]. Ac-
cording to our previous phase II study on biomarkers for
everolimus, elevated expression of baseline pS6 was sig-
nificantly associated with higher DCR and progression-
free survival (PFS). More interestingly, a relative decrease
in pS6 expression by at least 1 IHC score was also an inde-
pendent predictor of superior PFS in that it might be a
relevant index reflecting the extent of mTOR inhibition
[8]. Increased levels of pAkt and 4E-BP1 expression wereFigure 4 These serial CT scans demonstrate the efficacy of re-treatme
during the period of re-treatment with everolimus for over 2 years.observed to be potential predictive markers in more re-
cent literature [13,18].
Here, we present an intriguing case of heavily pretreated
AGC with liver metastases that was successfully controlled
over a year with re-treatment with everolimus. While it was
reported that rechallenge with mTOR inhibitors can be ef-
fective in metastatic renal cell carcinoma patients who pro-
gressed on previous mTOR inhibitor therapy [19], this case
is the first report of a durable control of metastatic GC with
everolimus re-treatment in a patient who was previouslynt with everolimus 10 mg/d. The liver metastases remained stable
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that the primary tumor was found to harbor one hotspot
mutation in PIK3CA and expressed high levels of pS6
(serine 235/236 and 240/244) as well as weakly positive
PTEN on IHC staining before everolimus re-treatment. In
addition, the baseline pS6 overexpression decreased pre-
cipitously after everolimus exposure, whereas the intensity
of PTEN was notably increased in follow-up specimens.
Considering previous studies on biomarkers, PIK3CA mu-
tation, baseline pS6 overexpression, and loss of PTEN may
all have contributed to the successful control of refractory
AGC in this patient. Although little was investigated on the
significance of reduction of pS6 expression reflecting the
decreased activity of S6K, it might be also related to in-
creased sensitivity to everolimus. Hence, these molecular
changes might be considered significant predictors for sen-
sitivity or resistance to everolimus. Another encouraging
but somewhat confounding aspect was the satisfactory out-
come of everolimus monotherapy not only on initial trial
but also on salvage treatment with respect to disease con-
trol. Everolimus exhibited a DCR of 56% and an objective
response of 0% in phase II trials, which suggested that the
major role of everolimus in AGC is control of the disease
rather than shrinkage of tumor volume [5]. Consistent with
these results, our findings revealed reproducible and suc-
cessful DCR on retreatment with everolimus in a patient
harboring potential molecular biomarkers, even the patient
experienced disease progression after initial everolimus
therapy. The major reason we re-treated the patient with
everolimus was the previously achieved satisfactory partial
response over 2 years on initial trial. Considering the tumor
heterogeneity of GC, we may cautiously speculate that the
most sensitive subclones to everolimus would contribute
most in achieving durable response during initial treatment.
In the context, there would remain relatively sensitive sub-
clones serving a key role in maintaining the stable disease
on everolimus re-treatment, These subclones might exhibit
higher sensitivity to everolimus than remnant resistant
subclones, but not higher than the most sensitive subclones
previously responded in initial treatment. Hence, it
seems reasonable that the best response of everolimus
re-treatment reached only stable disease which was in-
ferior to that of initial therapy [20-23]. Although the
mechanism of the resistance to mTOR inhibitor is un-
clear, disease progression after initial everolimus treat-
ment may be explained by evolving progression mainly
due to proliferation of the remnant resistant subclones.
Activation of alternative signaling pathway as MAPK
pathway in compensation of prolonged mTOR inhib-
ition might possibly take part in emerging resistance to
everolimus [24].
Taken together, the prediction of sensitivity to everoli-
mus using tumor tissues might be the most critical aspect
on strategy of everolimus treatment, and this should bebased upon the reliable biomarkers. Considering that
AGC typically proceeds to refractory disease and that
prognosis remains disappointing, this suggestion seems to
be quite noteworthy in that findings herein may provide a
milestone for optimizing the treatment strategies with
everolimus.
In summary, this case demonstrated the efficacy of sal-
vage everolimus monotherapy in the disease control of
heavily pretreated metastatic GC in a patient with poten-
tial biomarkers. More importantly, our results suggest that
close evaluation of biomarkers in tumor tissue may be
helpful for selecting highly favorable groups among vari-
ous subpopulations with AGC. Mutational aberrations in
PIK3CA and PTEN and highly expressed baseline pS6
(serine 235/236 and 240/244) seem to be significant and
reliable biomarkers for predicting the treatment response
of everolimus. Thus, in refractory metastatic GC, patients
with these biomarkers, even initially treated with everoli-
mus, might be considered potential candidates of salvage
chemotherapy with the drug, although further investiga-
tion is warranted in a larger population cohort.
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